Aurobindo Pharma
Aurobindo Pharma Limited, commonly known as Aurobindo Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Hyderabad, India. Founded in 1986, the company has established a strong presence in over 150 countries, with significant operations across North America, Europe, and Asia. Specialising in the manufacture of generic pharmaceuticals, Aurobindo Pharma offers a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and biosimilars. The company is recognised for its commitment to quality and innovation, which has propelled it to a leading position in the market. With numerous regulatory approvals and a robust pipeline of products, Aurobindo Pharma continues to achieve notable milestones, solidifying its reputation as a trusted provider of affordable healthcare solutions worldwide.
DitchCarbon Score
How does Aurobindo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aurobindo Pharma's score of 31 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aurobindo Pharma's reported carbon emissions
In 2023, Aurobindo Pharma reported total carbon emissions of approximately 941,472,000 kg CO2e, comprising 447,207,000 kg CO2e from Scope 1 and 494,264,000 kg CO2e from Scope 2 emissions. The company also disclosed Scope 3 emissions, which totalled 941,472,000 kg CO2e. Over the years, Aurobindo Pharma has shown a commitment to reducing its carbon footprint. In 2022, the total emissions were about 858,885,000 kg CO2e, indicating a slight increase in 2023. The company has not set specific reduction targets or climate pledges, nor has it disclosed any initiatives under the Science Based Targets initiative (SBTi). Aurobindo Pharma's emissions data reflects its operational impact on climate change, and while it has not established formal reduction targets, the company continues to monitor and report its emissions across all relevant scopes.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 409,572,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 523,611,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aurobindo Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
